Vincent J, Elliott H L, Meredith P A, Reid J L
Br J Clin Pharmacol. 1986 Apr;21(4):401-8. doi: 10.1111/j.1365-2125.1986.tb05214.x.
The possible racial differences in alpha 1-adrenoceptor responsiveness and the blood pressure and heart rate responses following alpha 1-adrenoceptor antagonism with trimazosin have been investigated in matched groups of six Caucasians and six Nigerians. There were no significant differences between the racial groups in the blood pressure and heart rate responses to oral (200 mg) and intravenous (100 mg) trimazosin. alpha 1-adrenoceptor responsiveness was similar in both groups after placebo and following both active treatments. There were only minor pharmacokinetic differences with the Caucasians having a larger volume of distribution, and a longer terminal elimination half-life for the metabolite, 1-hydroxy-trimazosin. These results suggest a similarity in peripheral vascular alpha 1-adrenoceptor mechanisms and show no major significant racial differences in the pharmacokinetics and pharmacodynamics of trimazosin.
在六名白种人和六名尼日利亚人组成的匹配组中,研究了α1 - 肾上腺素能受体反应性以及服用曲马唑嗪拮抗α1 - 肾上腺素能受体后血压和心率反应可能存在的种族差异。两个种族组在口服(200毫克)和静脉注射(100毫克)曲马唑嗪后的血压和心率反应方面没有显著差异。安慰剂后以及两种活性治疗后,两组的α1 - 肾上腺素能受体反应性相似。仅存在微小的药代动力学差异,白种人的分布容积更大,代谢产物1 - 羟基 - 曲马唑嗪的终末消除半衰期更长。这些结果表明外周血管α1 - 肾上腺素能受体机制相似,且在曲马唑嗪的药代动力学和药效学方面未显示出重大的种族差异。